Laura Dember

Nephrologist, Professor of Medicine and Epidemiology, University of Pennsylvania, Philadelphia, PA

[LaShyra Nolen, MD, MPP @LashNolen]

LIFE UPDATE🥊: Next week I’ll be stepping into the ring at the MGM for my amateur boxing debut to help #KOCancer!

3 months ago I started my journey with @Haymakers4Hope to raise $10,000+ for cancer survivorship & I need your help to compete the job!

https://t.co/dbY0g2fjbk

1/

[Swapnil Hiremath @hswapnil.medsky.social @hswapnil]

@escardio on diastolic BP targets
for everyone
Treat if > 90
Aim for 70 - 79
Class IIb recommendation
(Ray Townsend would have prefd an additonal DBP < 90 class 1A rec)
#Hypertension18

[Laura Dember @LauraDember]

@STMninja DONE!!! How can I say no to Nijsje?

[Laura Dember @LauraDember]

#AmyloidosisJC next time maybe I'll understand how to use Twitter! This was challenging but fun

[Laura Dember @LauraDember]

@Amyloid_Planet Esrd events will never be high enough for small trial. FDA was involved in establishing endpt for trial.

[Laura Dember @LauraDember]

@vsanchorawala 2nd trial required because p value not low enough to approve on basis of single trial. Most new drugs need 2 trials for appr.

[Laura Dember @LauraDember]

#amyloidosisJC Brendan- can't remember s but many more pts enrolled from Europe than from US

[Laura Dember @LauraDember]

#AmyloidosisJC AA amyloid is challenging from trial design standpoint since so much heterogeneity in underlying inflammatory diseases

[Laura Dember @LauraDember]

#AmyloidosisJC. Historic event ---I Just sent my 1st tweet ever! 2nd trial of eprodisate is nearly completed.

[Laura Dember @LauraDember]

#AmyloidosisJC

[Laura Dember @LauraDember]

@brendanweiss

[Laura Dember @LauraDember]

@Amyloid_Planet Hi -- Laura Dember from UPenn. COI: research funding and consulting fees from eprodisate trial sponsor.